PODD - Earnings call transcript Q3 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Third Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations.

Deborah Gordon

Thank you. Good afternoon, and thank you for joining us for Insulet's third quarter 2024 earnings call. With me today are Jim Hollingshead, President and Chief Executive Officer; Ana Maria Chadwick, Chief Financial Officer and Treasurer. Both the replay of this call and the press release discussing our third quarter results and 2024 guidance will be available on the Investor Relations section of our website. Also on our website is our supplemental earnings presentation. reference business for updates. to key summary you and metrics encourage that a document of We

namely this non-GAAP forward-looking Before performance. the effect adjusted and explanation measures certain current in Insulet well. statements. as These of our statements such are with begin, assessing expectations. inherent our made may financial performance we period we revenue uses the the to revenue, also our currency excluding measures for We'll by management from they limitations is during remind Please helpful refer SEC the of in to of cautionary differ EBITDA filings for which could supplemental what of respect materially constant exchange. and you to measures period, others that as operating believe call discuss align from and be growth, statements with course detailed a foreign we

will and stated, Additionally, revenue all otherwise that, changes on exception which the basis growth call unless a a regarding rates, of currency the to will over financial dollar year-over-year I'll constant basis. With with be Jim. reported percentage be year-over-year commentary turn on

James Hollingshead

afternoon, to outcomes customers strong in Deb. drive new of our type Near and and clinical the for of FDA set saw you, submission a which health X, we of our in back is the half standards management for delivered for strength am momentum you label and powerful data. impressive in create our across testament proud revenue another the I the full business. success generate history. Good first carried and better organization. Thank track clearance several of to over first the every diabetes day The to has the year half, outstanding another August, us. We for X putting billion expansion into our team our we year quarter us Insulet's for in time accomplishes robust year Omnipod received joining results financial $X out throughout this of close thank end achieved milestones on of and what

typical winning in our seeing remain in X, during every expectation in fourth for and the #X Europe. excited growth. foundation year. This Omnipod the Omnipod insulin Omnipod third global included populations. sequential in considering grew the our pump slower the upon in growth seasonality X customer diabetes quarter, X markets. in international the the year-over-year X established quarter. users long-term in new we prior for momentum our X Internationally, also of type demand building opportunity robust U.S. sequential sequentially pump about continued Proof which We it is We strong is our confident In strong months customer new offered in growth sequential stable the new both of that are are is now and our the with type starts over market customer market and and occurs in international the our both starts. the and for for new starts type and U.S. summer

and We the and in U.S. have platform, a focused Omnipod the type X on and international clear type X driving growth both accelerating strategy expanding growth in X expansion.

guidance. I by commercialization and will dollars achieve drive Our in momentum our and market XX% is the progress our strong we recent our goals. as you highest quarter we financial revenue of key will label QX, of to efficiencies financial growth revenue In our make milestones across quarter through for continue are Omnipod execute my first, global the growth scale, we on momentum an and And driven our take total details this X the to focus XX%. XX%, of opportunity type achieved update the remarks reflected expansion, of business. the continue our plans. of And growth X total across including we and indicators key margins our results. on areas: and strategic international expand to Ana U.S. provide organization

how Second, our U.S. growth it supports strategy internationally; market cascade the third, our of customer drive and both base and innovation, in and to and our leadership.

now to Let and form recent which type all already game-changing with deliver we benefits and offer the X ease be individuals we widespread channel. AID namely, X X thought that use, it we type label pay-as-you-go bringing economics X for X And would are me X pharmacy our of Omnipod access be. start and unmatched factor, with X, type diabetes those diabetes. expansion, both through first only type makes indicated to system Omnipod to the with continues affordability, type the the

X trajectory. with growth and of All Omnipod integration all importantly, label strengthens delivering further this, while iOS outcomes together with most and Android and and type based CGM quality compatibility our of expansion life. clinical smartphones X's great

X and market our majority quarter In over intensive XX% are market U.S. adoption million third is type September. with than Insulet estimate by We available to approximately insulin-requiring commercially for multiple includes with the the penetrated we who insulin ramping less starts injections. X.X In Omnipod the Omnipod. of the type X our who U.S., X live users indication customer addressable million total fact, on X This X in X% market making daily people that current diabetes. type new expands people during of users using drove represented as significantly

portion other sales at to force are day. X commercial and underway patients, to market on align an as type we our the million expanding expand with our to the insulin over relationships to therapy reach use well opportunity order every initiative includes of basal-only continue The people X immense that In a hand.

of into growing the with process practices build street today. earlier the strategy type begun commercial This population we And team our anticipation this With into prescribing interest. we to will on also while type practices, U.S. able year, the playbook, also great expect X expansion, our feet with on already high be adding over to our relationships XXXX. have deeper We continue we reach to reach of is endocrinology clearance practices. inbound this XX% in of during PCP and PCP X to where our are expand broadening go X.X consistent million established we existing receiving insulin-intensive

selling Additionally, DTC. we our continue to complement model direct with

individuals efforts XX% those our Historically, will X we X. are expect type We type customers DTC even and to now more X with leads of can label make Omnipod DTC our efficient. expansion awareness get and from on diabetes, over quickly initiatives our

are driving further these as to margin and all of thoughtfully demonstrate, our expansion. We are making investments we QX results committed

Plus our following full we GX how we pharmacy in broadly also addition fully strengthen to Dexcom's are track that quarter, the specialty targets. even on U.S., the to the Omnipod U.S., channels with market-leading pods release now sensor over customer compatible has Omnipod be discuss launch through in making X with starting the This starts cascade the of in GX X. X announced proven Let of innovation the we specialty ramp expand Omnipod would our pharmacies to have our announce consistently year. to of Omnipod pharmacies and now with retail easier retail happy innovation, of and in GX very available Last customers it pharmacy, this by on of we market to the GX choice me having Adding Libre pods our platform. integrated Abbott's continue X as approach are communicated and cascade end start X that months. met to I'm we effective FreeStyle position to

smallest The recent our Gap] as success became enjoy great technology. to on to the simplicity, track from sensors are allows with to just previously extremely app years, customers build have bring so foods the only X Omnipod making of and of with simpler. iOS this in that personal the here smartphone We both do and haven't iOS Potters, capabilities line is timing. of app we positive. markets. first providing advancement GX, app with enhanced integration X innovative in one sitting and the fully us GX and although planning medical and great starting through the to relief. just We are launch last heard of the Gap] are carry choice to much." the X our growing that France Netherlands, much unique [Audio custom X expanding users able Abbott the our we and app launches app market and to launched Within launch, At hours excited as piece to top is in experienced lives felt offerings. And in in makes the remain Omnipod with and early, I a U.S., provide our our as in downloaded U.K. feedback CGM that been normalcy the means new being offers daily of are Omnipod activities X how iOS our "I'm in freedom who customers the need a mealtime Dexcom of Early in in half Netherlands with told with customers is to healthier we timesavers we and [Audio and progress the of we my planned the number has options more feature biggest week, of start Store. normal the it huge with U.S. such overwhelmed XXXX. that our for Internationally, means. App this Integrated in Omnipod crying communicated, app both

XXXX. Omnipod launch early track are We on in to starting additional countries in X

expand of the sensor GX international FreeStyle X Libre Plus launching We and with first our to in are choice the offerings additional of Omnipod integration introducing also integrated further excited half X XXXX. with of

to customer now leadership. our Turning and market base

the It Omnipod By XX% approximately of This our Omnipod approximately U.S. the is continue be goes. using quarter, set X were standard wins a were power of as Omnipod everywhere an of our of with customers. to industry the international leader the We to already XX% X. X. it third customers testament and end

therapy. large target injections out rapidly are as opportunity Our bringing our we base increase present our remains focused MDI on strategy continue customer market and people onto a market drive expansion. multiple users to overall of daily and Omnipod

was MDI. from in new the decreasing growth customer by starts quarter driven third Our

market differentiated previously remain As leader clear a of new over MDI. came of on due people the U.S. We the to nature Omnipod. XX% result, highly from customer our starts

economies scale. and of We led decades our have that have to X investments experience growing of

produce distinct quarter, capabilities. manufacturing, to which high-quality of sustainable including to Adding further competitive the our our Malaysia state-of-the-art of which world-class allows and celebrated opening during we flexibility have We the grand us facility, provides tens of our scale, millions manufacturing strengthens advantages critical. and safety

to investments U.S. through channel significant the have and customers. This is build we a important specific our an access expertise for the infrastructure journey widespread multiyear today. proposition Additionally, pharmacy deep value was requiring

We the pharmacy paid investments of our pods to that through XX,XXX. now our Omnipod XXX% channel of over growing for and nearly number are HCPs with X, writing proud time have off the with sold

We creation. With that, are value today about and catalyst we walk drive to to I that to call through will we expect guidance. sit long-term over our excited Ana the where significant you the results further and growth turn

Ana Chadwick

Jim, and afternoon, you, good Thank everyone.

we global and another team mission, Our results. continues financial of our quarter strong to on execute delivered

quarter Third growth driven expectations. Omnipod revenue of by We achieved our exceeded growth results total XX% XX%.

global estimate than higher remained was prior utilization slightly retention and year. Our stable

and both U.S. starts As grew sequentially. customer we Jim global mentioned, new

the growth had was of XX X. for versus range, our points on guidance end driven ongoing revenue reported Omnipod XX%, currency high demand impact a by Omnipod strong near guide. total our favorable basis finishing company U.S. Foreign of

GX Our from And gaining primarily base. Omnipod momentum. quickly customer driven is expanding be X the by success our volume resulting U.S. our growth continues with revenue to integration increased

about further that are label We to type excited growth the in business. X brings Omnipod drive X our our opportunity expansion

clearance, type nature an following meaningfully expect new the of we model, starting XXXX. in our FDA to We are starts annuity seeing X customer revenue uptick to given contribute the in which,

were consistent U.S. the prior Lastly, utilization with trends year.

achieved still growth year's again well Netherlands and In are our strong for Turning of with international Germany for drove QX, exceeded early Omnipod are while launches Omnipod continued We our fueled seeing international France to Last increased And as in integrations demand driving Libre and primarily growth delivered demand team International, the in expectations. customer by U.K. X we in our of days, in revenue another once sizably impressive all revenue growth Omnipod X. quarter and as our Plus. where we XX%, for and the recent X new starts. markets.

early prior trends benefited International volume versus the growth higher over foreign year utilization above up On margin pricing points from contributor XX.X%, basis remain existing our X XXX favorable in was revenue positioned the further revenue initial in XXX driven While due growth, remained following an to starting Delivery in a was efficiencies. with Omnipod X XXX markets the due ongoing our basis largest well as as million, the revenue partner. what currency U.S. was X. Omnipod prior X we by pricing and new and well is We manufacturing launches to Gross Drug customers to International adopt benefits more from both basis, for $XX channel points points, versus which range guide. basis guidance elevated Omnipod orders, pharmacy our year international as Omnipod saw also orders to improved similar was the launch. our reported U.S. primarily slightly and increase higher XXXX.

expansion to and margin revenue and across allowance. discussed margin of balance as business. XX.X%, business. $XX quarter, out has quarter. of EBITDA margin and a throughout anticipate our we release in the excellence adjusted as scale a of expectations, the we realizing non-GAAP an gross released our additional third adjusted valuation in leverage quarter, strong operational a of our $XX are million, driven which we period, of the the in benefit by We as drive for remaining In to million tax perspective, our resulting last continue the tax purposes. drive releasing our the we execute From fourth XX.X% performances been exceeded both noncash portion operational initiatives our on Operating We well

be and We continue well. to to XXXX the XX% non-GAAP range be in of expect to our tax rate the rate effective this XX% XXXX to for as in

liquidity. approximately ended with million and cash in We quarter and available facility. million credit to $XXX $XXX our the under the cash Turning full

financial in growth profitable ability is resulting to Our free business expansion, invest cash strengthen overall in profile. drive margin positive to paying and flow our commitment and up, our our

our fourth our to turning with outlook. Now Starting quarter revenue.

revenue total total of XX%. Omnipod expect We XX% and to of to growth XX% XX% growth company

X% XX%. For to of U.S. Omnipod, we growth expect

the is the a to growth $XX As an approximately estimated benefited stocking normalized to in $XX reminder, underlying million. midpoint the On guidance be in from fourth XXXX, basis, of fourth in X XX% million dynamics, quarter a XXXX we expected totaling quarter the of range. of

basis, favorable of points. XX% we XX%. impact to a we a of now currency Omnipod, International assume growth On basis reported For expect foreign XXX

Finally, $X million drug delivery approximately million. fourth $X be we revenue quarter expect to to

a full of expect As our we fourth expectations, result quarter now year. revenue the following the for

revenue of year. of We for again total Omnipod once a growth XX% to XX% putting to are raising for revenue us of expectations the $X a total XX%, range range to XX% total over billion to our and growth company revenue

guidance Omnipod, growth to U.S. range we expect the For our end now raising revenue and low of are of XX% XX%.

on to our point of foreign tailwind from revenue On to XX% basis now International assume we XX%. range a For reported Omnipod, raising are growth a basis, we a XXX expectations currency.

with revenue full International strengthened X, success X,XXX in the points by raising is resulted are outperformance of year by for achieving start which our significant we Our international has are outlook Omnipod the XXXX. since Omnipod outlook and business basis

Lastly, for outlook we a in the drug XX%. and X% of improved, delivery, smaller to now has our expect range decline

Turning to operating and margins. XXXX gross

strong now our in margin we be confidence our gross to to approximately XX%. Given outlook, expect performance and date

margin and gain continue operating continue further even improve for committed profitable remain to driving expansion invest we also leverage, across to efficiencies as growth. long-term our to the heavily organization We as operating we our

continues market to guidance another raising again are be a leader. basis As closing, result, points approximately XX.X%. In operating XX Insulet once the to we margin

many free to invest our growth continue cash and ability catalysts. to profitability flow expanding our drive in Our

cascade for innovation market please long Our expansion sustainable growth. With our questions. strengthen the open profitable line runway for operator, and that, of

Operator

[Operator from Instructions] of question Our Bank Steed first America. comes Travis from

comes next Our JPMorgan. question from from Robbie Marcus

Robert Marcus

third nice really a X on My question. Congrats quarter.

really #X Europe pricing out patient said was quarter, it you and This beat, stood sizable new winner help.

if magnitude new number few which we selling #X Is countries overall in X or would impressive. sustainable how the hear Europe? more to U.S. things. that think clarify patient and happy I do we benefit is wanted as price want and growth, to So to that? And about is a is go do that just the about the in really well, help to And of be in think how much how that. there you in, How of throw in just Europe, you're

James Hollingshead

Europe. Robbie. in Thanks, for question, for The the and Thanks congrats. we serve your in thanks is markets the #X

because, we think impressive #X all the course, we across. reason is we we're have So don't that's markets And Omnipod the yet serve. X of in

#X we're countries where internationally, the Omnipod pump. X present So in the is

quarter we that been had of strong The growth the so a has way. terrific. really And magnitude

Germany ramping, that to Netherlands and So and strong. continue. we just and continues really France U.K. are expect

pleased but part question I'm the really new starts remind turn we're going had with a U.S. maybe And the second second me customer can of growth you on was. in the to Europe. U.S. the what So Ana, to somebody

Ana Chadwick

Yes. where way Maybe Germany touch Omnipod the a period. getting about and like present that we've pricing it time think longer to X is markets international. to been anniversary are bit I'll The in on with U.K. little

we be not in early XXXX another going into is in going XX We ramping are will bump that we'll be their markets, to So see and And us ministers the gone launched that they remind X, where by because France have we've go to value. that just some through we up. variance, having health as a to move ones here. we've premium -- annual Omnipod but anticipate out cycle but we given new the markets anticipate stages, ministries, year-over-year for they be you, to as way, countries those rolling new a

to markets other we of accretion So Maybe as the part into is move XXXX. line the international the bottom question? price see in we anticipate

Robert Marcus

magnitude growth? of patient on was It new just

James Hollingshead

Yes.

quarter, stable the was would seasonality summer Europe patient terrific the we in growth months normally some see new cyclicality, some Europe. in So in because which in was

with are to beginning So stable, customer really ramp. in starts just strong new particular, France,

So both had pleased type X that. -- starts, we really growth with clear in strong way and were U.S. in in with sequential with strong and U.S., we And the type the MDI. new good then customer X leading the

Operator

Johnson comes Baird. Our question from next Jeff from

Jeffrey Johnson

question. Larry don't want steal guidance I XXXX to Look,

on X spare does much because for in keep last points there's X TX TX, equal that of penetration of have business of the something the year year let I X at I When maybe there',s, I manufacturers, TX. points when or that been question, to I year X more I X time. higher-level X really plus X or points So to a of when handle PX I the penetration same know, X about the point I going your think so X. X, kind U.S., is it's past market? Can more this the don't bandwidth X over penetration the pace at prior the that broadly, or think industry look payers, adding moves across in capacity if X think a going to each X or the even me a to manufacturing potential with each been uptick penetration constraints TX because a HCPs, and Doctors X Or only about TX, when probably does be we've headwinds, front. in Jim, X.X could. this or guess, about points isn't X here year less industry, think TX in I annual bit start of and going is there maybe to year the

James Hollingshead

little a of great Thanks, Jeff. It's a a That's question. complicated bit question.

from just of me doing. our it and point answer let dealing view, So what

lead to X. and extend continue We type

they're drive very continue leaders. growth clear We MDI where to into

extend market, MDI and penetration lead to So we player and because the leader the X drives leading type course, to our continue which, clearly in of we're the that's intend market. the be growing in

AID an the penetration type low X saw On type we in X, X additive that and a is in we The in for side, September. as see nice lift type very opportunity.

in our good really use for position and as X about with indication So there first in player space. we the AID an type only the feel

days. or certainly the in handful can already development, In terms And will of years, maybe some and will we take think over penetration seeing both grow type we can the penetration next grow type of grow the span, both, number, Xx over we beyond, X we're Xx a X it's the but market lift. early

to And continue that leading and we'll we'll and X both type develop be and developing X. and market, type so lead

Operator

question next from from Our comes Bank of America. Travis Steed

Travis Steed

to but this guide higher in with kind Not opportunity about you've to on Larry's got call, on patient think with a I level of X. but I new thunder, the know type like not going XXXX XXXX to like would starts you're

how at move takes thinking landscape Just 'XX would kind competitors this of you're you're as that all on well. love And about about X of competitive point? you your as 'XX thinking to the puts into and talking the dynamics, competitive hear

Ana Chadwick

with these start positioned I'll dynamics. competitive here of and fourth excited Great. maybe an will here some quarter. prospects, Jim and the with guidance where in in we're as the with we're jump end to growth our coming we're really But

We as point, indicated return of with color, industry drives be at revenue, to we'll to But we to our complete marks annual to as I'll what best entire are here And here, P&L which you just some providing cycles. get you most give and start the is provide February our picture. and standard that here. the going to of guidance we're able the --

that's very Really those seen things. where U.S., cascade innovations. well customer the the aware in You're starts launched you've uptake types in And second of of and new the the they half. here sequential really of

markets some you we're come ones start I that we revenue of annuity international ramping. we'll through cycle model, so earlier, into the will move growth about we as go new XXXX. then and started And know, markets, where anniversary launched for most talking in the As will that

in now on growing our the come the dynamics. where NCS. as the are majority start from we the markets grow bit we're international the So greater again, strength price little of in our believe I've base right we key growth U.S., a of that already touched customer we're going will those see to

and color move very feel well provide a we you we February. again, lot So positioned, as into we'll more

James Hollingshead

have Ana. chime Travis. say, we competitive And market. X just I'll competitive in here's what dynamics lot that a do dynamic, just competitor comments Thanks, Yes. I'll We on in the the on the know.

that that remains kind retention industry-leading we've and competitor, And from of row quarters X. have of an very X to X in actually stable. regard on noisy coming high We now with to them conversions seen a uptick Omnipod

we in what just are ever on on competitive daily differentiated part by I'll on focus the would that's clear X injections, But So Omnipod leader therapy. to is on I who are we bringing of the the MDI, the so actually we to all market everybody growth -- market. launch, Omnipod in multiple our that remind very people about. the know. it the X talked driving on is use. focusing by platform way, remind and patients And coming that just enjoy find It MDI have continued we've easy since because to the to conversions advantages has

of continues since very would therapy -- we every of off X I XXXX, of today. that on competitors combined patients launched X dynamic fact, Omnipod to we and have In our than more clearly coming ever Omnipod quarter, AID in with MDI all added August

Operator

from Our comes Research. Wolfe next Polark Michael question from

Michael Polark

what on cycle, type wallet time. how then X. opportunity kind in of just much of rep One, on there. investment, XX,XXX X a have you buy? of ever are expanding I kind U.S., on Omnipod be the the X, X X, might a for have the you're X. interested part HCPs through I'm to the this dash a is question those Part X it's right of folks on the quantify versus doctor can X curious the written Maybe do you force for parter. That's preparation cumulatively HCPs a for the field have when prescribing type you side. heard share those how I commercial script, type like base Type first just the for sense getting get

James Hollingshead

way, guide. to I say, It's is quantifying don't our questions. and let spending Great we get opportunities. me into guide, targeting in try -- question I headcount according our doing actually want what lot a this we're our spend. more is what we've commercial margin accounts. into and gotten XXXX or better Mike. Thanks, conflated in current the model But answer is your extending to which are during And

So model writing and we're doing that commercial point you been into historically endocrinology has what know into our is PCP call extending high that current our with practices. most taking also of practices,

And as so would MDI-type maybe X therapy. think extend XX% those current X our put some we insulin-using intensive to to are say, north get type practices, or I point, scale of call users XX% of insulin type on of in, roughly MDI who in reached we so into we high-writing patients. we And those

more a basal-only of expand from our give scale sales expanded sales then the of to expansion type of us consistent a extend reaching well. of But about also those as patients treats will XX% to call so patients we thing users those just get rent type about Now you current basal-only of point that higher sense we'll of to those X mix patients, high very might and some and that do the the has to It's actually for force. reminder, as XX% a And we've here the intensive users. force. X a

model done to extend robust QX successfully in and 'XX. into we've now we're very some 'XX, in So and commercial same expansion the planning

Operator

Our Antalffy next UBS. from question comes from Danielle

Danielle Antalffy

quarter really Congrats strong on a here.

it come Omnipod about beat how U.S. specifically, below at line a the question midpoint consensus, we the thinking but Just quick you item does just as and you're in the about guidance QX the number. think consensus

anything sure is everything usually make make a a I seasonally in sure I'm what perspective deductible we're and quarter So stronger considering want there. just to not from missing

Ana Chadwick

a than year. correct. more actually it's drivers. guidance And Great. we well I midpoint, that for of we of within really guide, Thanks, the is Absolutely U.S. online calendar growth Omnipod the activities grown high at Danielle, end At everyone, the just XXXX to normalized and basis We see want of a consensus the remind below your trajectory, that U.S. consensus, falls traction XX% for lot a it XX% it reflects, we're the But our in stocking on our question. see a line. Omnipod here. the that have great ago. saw and We each quarter positioned reflects and -- will year

reflects available moment, we're our and what Our guidance giving that's best the you information at all. really

So midpoint and well excited very the be U.S. full very the our positioned range XX% guidance to we at mark year at for are of

Operator

Stanley. next Patrick comes Our Morgan from question from Wood

Patrick Wood

just you from market type you have you already the had that X from into curious ramp me, hit curve juggling that you that but on that cleared, could improvement obviously, thinking [indiscernible] calls I'm was move label the quarter. Yes, surprised X as today, the through you and if patients. side of any would like what I you apologies look learnings of just your of feedback an some as this, said things, move there lot next but that know about already, year. a

your get you that there are both And surprised as Just expectations? has anything feeling how you the your previous it? feet you on been ground,

James Hollingshead

in got label. of because I much I'm it didn't Thanks the we would them say We first we in We clearance -- our expect to Patrick. team for expect QX. the go question. until later Thanks, with QX, didn't and did so proud

really a proud needed to was ability and I clearance. done so to we everything And get team's to together that our done get launch of pull

the in patients MDI from terrific. a that are type was X. coming see from MDI, did September that so And we And lift

lift was side. X a it the on type nice So

patients practices over we've that as the learned there course that month tested model that I we is and but also both of GLP-X, First, in the struggle think of still Go X in out our into control. the Omnipod of a a on went They type world the lot have out with AXcs who insulin what there pilot, really therapy. might September, and just still on be They they of out glycemic are control. are

keener things thing those So really and we once are how use secure interest X other it in PCP the already AID I TXD to understand learned cannulas see and patients Omnipod interestingly, how have benefit expectation. needles maybe that really see how market many is. X demand that who by we was as there's And have high-writing simple promote. they that have that see is they Omnipod, not a tubed so of lot they when practices can conception hard those of historically prescribed And a that sites because was preexisting TXD, them, -- even them out so would see counter our with to clearly in was investigators and and the that they simple even we've big pumps we trial they practices, say with really Omnipod our maybe on. a And they showed interest SECURE pumps keen was have for their an to mentioned the that there. part technology, is the that things investigation for prominently of took -- And

controlled, people are even those So in to continuing bullish showing be that very ease and on need, need the already. GLP-X the drive clinical though And a given who maybe not pleasant given develop and market are interest X. And are surprises. insulin of doctors of on for on might Omnipod use the that they growth, the we're very,

Operator

from Our comes Fargo. next question from Larry Wells Biegelsen

Larry Biegelsen

I on a a guess, follow-up I angle but asked Jeff, man, a have smart earlier, And just here. different the do Danielle question, is

does Omnipod we if I QX the from you So XX%, growth, said, deceleration think, Jim, ago, about QX, the imply which adjust a year as a underlying stocking for in U.S. QX. is

type think underlying launch XX% X the accelerate we the about underlying or of U.S. growth Does of the the should growth how So maintain context growth? off Omnipod QX in the XXXX?

Ana Chadwick

one. that with start I'll Yes.

So our going model, by a of our we're is to annuity to that. see these lot the of progress growth sequential into as that again, experiencing also given quarters and over remember The out NCS XXXX. here we're more of we're thing growth benefit XX%, we excited through

driver be I confident main that we the if for move So our as don't excitement know in there's... forward. would are here

James Hollingshead

start customer in start new growth estimates, I'll to we're Yes. be you. the had in giving dynamic, if lift have just the and to as we just clear even And new type confident without had said, U.S. back X. best with guide. way, very the that's very available approach what we go sequential feel add, we're our in I our Ana this obviously, We to transparent our would is by customer the

clear prepared in as the quarter, said in to to X. expect X. had sequential the this in expect last we said type in year-over-year we NCS said growth in So have Type clear we And in for growth half we our second and sequential remarks, in U.S. NCS We growth we have had we as -- prepared but our remarks,

in QX. know, guide gives in our The ramping confident annuity more revenue ramps even dynamic our will you into model, really create our guide. X clear. confidence We're type as But growth with So XX us is that effect. for the all a

Operator

touch Our It's for operating next here strong Margaret I comes Andrew really, wanted question performance Blair. actually quarter. this William on Margaret from on really Jimmy margins to tonight. from Kaser

your some sustaining So next as then leverage? the maybe relates you that of can driving confidence talk just that into to are it on that points to And year?

Ana Chadwick

No, you, -- that strongly that. we feel continue That's before we here what and margin said growth, least basis expansion. I've at said benchmarking margin Thank Jim, of we've to XXX we're we as we very to Great. will very points very we believe that. are for have before, strong that delivered continue. had annually and And

of Some key had. gross you tell expansion came can the margin components as have here margin, from we that

the the the addition, has operating that allowed well. expenses to in us In of we some as scale -- operating leverage have get base in

is growth from in Jim U.S. pharmacy In reason the benefited have moved for we're we coming in through anticipate XXX% into we that have as grow, of now, mentioned price to roughly the also And of more we volume growth And the forward. the gross to continue mentioned and have as we out we be in before. margin, pharmacy this appreciation as as moderate the we So the really our in margin, gross channel. prepared remarks, significantly at I move channel. anticipate DME the

there Malaysia do volumes from we have So markets, accretion. around come efficiencies be how forward, some we the other anticipate And going other we things. many that around but levers have lift in will and price a international of lot

to leverage our gross So in expenses. wrap we that, operating as have just of in we it coming leverage the scale have addition we up to And margin. benefits here, our from

Operator

Our next Redburn from Atlantic. from question comes Issie Kirby

Issie Kirby

Obviously, change ask to wanted basal in you're of seeing that as of about basal a providers on just And on any any things. that moving last to just type broadly, it's you had and I on your about now just sign are seeing more for patients on quarter the the a patients. flat more strategy what guess side, patients bit learnings from them. basal side wanted and hear and available to behavior that X then around these who value you're Omnipod paintensifying I retention to

James Hollingshead

Issie, for those questions. Thanks,

patients that the data they patients. already patients had to are writing -- patients, basal-only benefit start number with we indication got will basal on patients we TXD the for benefited. in simple physicians Omnipod suited injections. to it who so is promote well very, the The have And off-label we a Let know as of use in obviously out X use. those me And showed population were clearly daily population those of and before that that of have for study same patients the the market basal-only already have XX% a -- X We Omnipod just about basal-only and very we secured reasons. side. number multiple on who for is That been to really patients

as a more that's And target basal And is that the our be we'll read who's those extend to market PCP users That's high-writing and really not of both patients. on benefit and more controlled. question intensive into the therapy so there would And huge find we insulin and them. users. know we that's practices, out it's those

on a X of question. good really On the type bullish retention, we're market. sides both So that's

a base portion customer include X of patients. type does Our

has retention remained a on their strong. X We a They we'll X, that retention strong. has lives. what that going over comorbidities. but is lot Our do It's lot time have type of type anticipate very mostly remained our patients, in have see they

of see we'll patients. think X different I type subsegments

type in that X parts quite our all of would the And of usage tech patterns maybe population. see incremental those the some we'll think X it's But first, in likely parts lower business, retention say. I so different patients population, I to of and are different

of So growth over and as same patients quarters additional which X the of we'll as can next volume retention experience be it's given more X something them time, make that we Omnipod we've And so we'll over the really building and doing all historically. offerings type on therapy kind few months, patient market-leading for is us. to patients, work of additional with all their the patients on experience for more type and X customized several and just therapy be simple possible,

Operator

from comes Partners. question next Leerink Our Mike from Kratky

Anthony Petrone

some Can transpired commercial you've you provide additional within some much a of seen, positive this that either the color how own on both integrations your have of or CGM from impact negative year or any a an how these customer products commercial impact existing your are getting base start, of integrations would head having on meaningful say a dynamics. or starts or of you new bit competitors

James Hollingshead

to don't I'll Ana and commentary. if want Mike. will add I know Thanks, with start some that,

us been have for our for and Our integrations terrific sensor patients.

new retail year U.S. that through middle start the the fully the with of described a the our patients high GX well obviously that's GX. were very market. successful sensor in We with of market. are in still launched U.S. been obviously, So U.S., starts. in now pharmacy material GX, really and we in the lot And specialty the part We really customer a as our in of GX integration,

integration. we've then in Europe sensor the has big the providing launched recently start and So a of our a to Netherlands. we choice [indiscernible] and U.K. new choice most in growth. obviously, you're, And of sensors launched with boom customers And the GX and integration initially been us for

be very both very the And and prepared done sensor year have by we Libre X Plus Libre integrations bringing of choice so remarks, our in of the the end for in really the GX we're And the both us. excited, to well are said the between to the inhibition customer those U.S. X both sensor growing as And Libre GX and well. those the has markets, Those markets -- Sensor. a

which the U.S. us every it's them, we've obviously is it's a tailwinds in customers to And choice new available sensors been given X to time to our integration, launched provides but center have growth. more also it benefit we'll a -- of customers, So

Ana Chadwick

recent But perspective amount mean with our applies with GX. a Maybe here the we I the downloads with most of the it iOS I'll with to continue that will to speed us U.S. more path now everything we're iOS refunding those in launch greater to launch that seeing future. just add in through success how customers -- gives are it available even of that the and have confidence our in that right

So that commentary. I just to wanted add

Operator

from comes James. Raymond from question next Jayson Bedford Our

Jayson Bedford

clarification a a question. I have So and

a clarification strength. international on the Just

benefit mentioned be the quantify. That's utilization. to was This a when a slight The X. To just natural clear, uptick clarification. no of Omnipod pricing, your European X context on XX% of stocking just launch there in users question user the XX% You Omnipod How base in on X, is occurrence you are adoption? your base in if just can Omnipod in high terms U.S. go is, Europe.

Ana Chadwick

first the take here. part I'll Great.

U.S., in maybe the usage the little but do what our a to just terms to product is later. of the get at with degree, saw similar X In we when of couple do smaller This once you just orders entirely backups international view people new strength their some uptick, to at -- a probably that get for nothing to launch with stocking. and we utilization

similar we're where markets international launched. dynamic some seeing we've So in of the that

James Hollingshead

James. this of of market, expect similar X, the I U.S. in in I'll how the in is as becomes very the portfolio, see including on on usage people but think over would we've X just AID I across Yes. international used we our before. are markets international it Europe, far there's omnipod Omnipod in products markets, contracts. Thanks, in our -- go high to X talked can the time, predominant a dynamic as it our Omnipod which will choice, own in And seen markets, about a base. international So bring our by be customer we've will

X-year to DASH cycle markets, to converting usually It's -- a the on contract for we'll for in Omnipod so from even wait X, period from most come reimbursement even And converting up. them.

international leading our it with X in markets the offer so won't but we've in see already pump time, the in just we'll we our #X in X Europe is move over in as the as see we Omnipod markets. And quickly, portfolio Europe And we said, markets our as clearly serve. launched

we see And internationally. X we it, of starts see rolled out really as as Omnipod can power so well you strong get expect the customer to new

Operator

Our from next question comes from Matt Taylor Jefferies.

Matthew Taylor

I It's up very guess the follow type I X. exciting to stuff. on wanted

what was just some with time confirm estimates I were Do research directionally? get with could to Do market a to out on frame your that? And wondering any guess done agree X-year Your X- U.S. I you type thoughts that you in you penetration competitor that's that? that the number put have the research think in XX% think ballpark they market for to the in intensive X

James Hollingshead

very question. bullish type a It's Matt. We're great on X. Thanks,

things go, pharmacy clear talk I up, first We -- easy have pay in get first in win we're because great all access, easy products you And such time. X X with so Omnipod all market all to and available in think have we the to the AID to right have all a market where of X And use, patients players insulin anything, market the we the AID market, X. the to easy has only benefits, set if about that the a type we're AID with the the as market. of the their I in the type type and with opportunity overtook

have the remarkable. The secure very, win X TXD type a really right is we very I space. So to data clear think

so it. we're on very bullish And

we us next early for X. optimistic who market right type space. days. very in in that it, double years, the think we're the that I we We're handful We're lead see a big does market. player penetration space It's the we're there's now. clear be very but the earlier the in that. the said and years will of in right we few #X growth We'll where think think could can or the Q&A type over developing the It's take growth X ones about we next market triple in now. over that the

Operator

comes from Piper Sandler. Our question Matthew O'Brien next from

Matthew O'Brien

Talk channel little a about the bit. pharmacy

the You've noisy quarters. had in a they on then durable few side yesterday, that signed. a got their also the you're over just mentioned contract competitor that space And competitor first last

pharmacy So specifically can they sure going on and you defend your once ability you they're to because position pricing pricing side within channel about the there, push defend know your bigger pricing to make your get on talk channel? and just in do that I the the more side bigger how to

James Hollingshead

you. in so the Omnipod pharmacy question. we saying a the channel. just well. Great because by have do very And position pharmacy I'll fits that Thank the reason channel start strong we is

it the Gap] [Audio reimbursement, we comes is pharmacy same, First Part the product box, in and consumable, D have reimbursement. benefit the is get you which a

So meets And the the channel. it the product the needs channel. of is the in all stakeholders

rebate X, easy we on It's our it's a it's they channel very PBM and patients often they member can sort because so of and that of they for down -- it's for reimbursement, prescription, a volume high partners for so a PBS money. prescription, to the off satisfaction write through write use. pharmacy very Omnipod great revenue do the in who local send that have patients because get So It's to it payers can to -- they're easy are who pharmacy. for just venue because can write for physicians of we drop-down for full our lot great much very a

And so our we're us positioned. strongly for system and all of business it's stakeholders, great very for and a

price negotiate us. very every We're year. win-win against PBM far volume goes, for As there our those There's it. contracts a We as rebates are for to negotiations. used

this we've years, great relationships. And built have relationships We several contracts. a is and up over capability

as negotiations PBMs signed We in have XXXX reminder XXXX. contracts industry. that. contract just correct and the many our We everybody, contract let in in first me a many, in started we our to no, process -- XXXX. sorry, We PBM signed And with first the

very a our PBMs ability space, confident we're to than this experience in we've of in more have now defend lot and X So position. had our years, contracts for with we

Operator

Next from Research. Nephron question from Pasquale comes Chris

Christopher Pasquale

where who for you how the quite broader on guys that work Is Could you're mentioned work It And some that to How like push or us right has broadly, narrow a doing offerings on of own stands? a an develop this there's you're have algorithms. ready give their managing it? engaged on applicability? better with segment front your would that patients about commercial having users disease. then do for job you fully could those seems actively Can as now aren't closed-loop you thinking something update a industry close the a use. helping solution that be across are something

James Hollingshead

Thanks, Yes. Chris.

current you results. at to is our programs. a and great know, talked just But publicly, The saying As separate start It algorithm produces me algorithm about -- let by have talked parallel about we something we ADA X we've algorithm. algorithm. Omnipod fantastic development

of corners see You can of usage. all all includes in which we users evidence, real-world see our from our effect,

and range low hypoglycemia. time very We industry-leading have with

And our also well so [indiscernible]. algorithm current responds to really

Omnipod when into is daily it to So deliver X patient of will significant back bring percentage insulin a total a [indiscernible], the range.

individuals So really at a all well population for our performs level using algorithm the really, and it. current

because different have been off with Now of on algorithm. fully say working having the of different both usage. But areas get I to would programs one X accelerated patient said evidence closed all loop we that, which actual two, we have concepts, of them a is closer of

quarters Omnipod, usage do Insulet to we were see was in to So even of XX,XXX that after ago, us able patterns patients the which first on allowed accumulation.

to So of us X that the programs data get to the data algorithm big capabilities simulate over we some of year. allowed with into last clinical trials to the algorithm, early use different what's that's we've our adjustments that data shared sciences and course and

improved we So But algorithms great real happy in to see couple be approaches, opportunity we're accelerate market also we to and we're now. program. delivering control glycemic drive a with know and to the of different outcomes able right that

Operator

Wuensch from comes question next from Citi. Joanne Our

Joanne Wuensch

about things, to a couple where of start. curious just I'm

GX. quarter the positive does impact of terms Libre confirm, step-up of did you new sort create you for event quarter? with to patients? a new more of And that I can I this that opportunity mean fourth have and you patient think going is of integrating Or I'm year-over-year? just a starts it in

James Hollingshead

customer for Joanne. tailwind the yes, the the us that in Thanks, then integrations been U.S. and the an give with And the obvious been tailwinds. X the with tailwinds We helps new has Netherlands. Plus our -- us Libre us starts. for in have sensors in GX launches U.K.

we for we the integration positive those we've delivered then opportunity growth, and will bring we year-over-year we U.S., are for as have growth and new see that for we starts X, in clear the clearly last all type very that So to really of half customer upon dynamic. we U.S., in starts the And think QX sequential collectively, QX. in see, will every in second expect year, us. quarter, the to growth as would And type expect growth us. to for type that terms grow QX in be that said have in sequential have U.S., growth both create year-over-year the X. and growth U.S. Libre In QX X based we another promised X customer we X in new tailwind will year, type the sequential and growth And in and both

Operator

comes Miksic Matt Our question from from Barclays. next

Matthew Miksic

patients obviously, in rate leading So you retention I and new to -- mentioned wanted started. the

overtaking or about bit I think, Can the about little and you at the retention with with pump how in a your you players -- talk how Jim, if space upper can it other just of talked you rock format. a to measure this would if color that's in how get solid bunch, trending, it's any XXs investors sense around mid- moves appreciated. if a kind be of all, the

James Hollingshead

Matt. Thanks, Sure.

users data. First, on majority in let me start the our U.S. the are X. The vast of market with Omnipod

that's So data. cloud

very somebody tell tell we has can it's started, can high when has So stopped. somebody when fidelity. We

So really data we this. clear have on

high. really remains retention Our

XXs, it the say, And room that's around in the, low I going runs sure right. to make so will look I'm the and

of experience creating really very easy going to very to stay very give and on, it doesn't that very build for stable. But stable. it's that very a to customers It's We're sense very, we're on So XXs, a low with very thing. it. move them build area. that's It's our capabilities in and and really high, to delivering in runs It very It's and stable much continue you predictable. period-over-period. and focused

Operator

Our last question Bill from will Plovanic from Canaccord. come

William Plovanic

and impact the the been to trying you've AID commercial know the what understand shift been just I organization. mean, if after has impact I'd I maybe gears. like seen launching on different system kind channels. to to to the you're scaling the But go just you've up this on been customer patient ongoing time on servicing over has kind basis? of on thought selling the you're more the this And been patients? of has of and lessening service with less an potentially where focused on -- than lessening

James Hollingshead

Bill. a That's great customer focused we're building question. Thanks, completely a Actually, really experience. end-to-end on differentiated

And or be that might -- customer they what the be people. fact, In because I opportunity with might their deliver capability that's of way and unique pods child out connectivity an a moment way might the Omnipod be end-to-end of we X. do life. have, the of starts cloud actually a talk the all this to diagnosed think, deliver about that we We internally for unique diagnosed they is we experience to

U.S. product remember, I launched so in think our that that What are when demand our the care, say phones. just time had really our a August period trouble X we there, might of so in XXXX, you all of I'll we had actually, the And for all support customer world-class. answering that we Omnipod much service, customer --

as unique we scaled behind scaled we've Omnipod our We've building care. our inside that. there end-to-end got that we product -- customer are experience customer of about scaled support trained. scaled had demand excited We've started, on opportunity our And to we're the get future they best the Those so our really sales. now capabilities. We're and time. days our in customers scaled users to support, so appropriately We've and do laser-focused We've product over really us. got was they our -- commercial much and the not when for

Operator

would further Hollingshead. time. I conference showing Jim to turn at I'm questions like to this no the back

James Hollingshead

all Thank you us for joining today.

us financial We and foundation that have strong market-leading to market-leading deliver positions to value sustainable that advantages competitive creation. continue growth a technology strong allow long-term us to drive

major employees, label our X another improve growth a growth X game and type stakeholders, X of diabetes proud all to with clear the for the the is both diabetes. disrupt type Our team including drive and X is milestone U.S. in and lives type market and people platform, Omnipod the expansion of expand investors, and With International and most HCPs the Accelerate expansion. strategy importantly, doing in changer to customers. I'm work our

passion quarter. in to momentum simplify further lives improve to their updating around want of next commitment thank look progress Thank have the with our for joining to continue deep forward organization. to and for mission globe. our everyone, us strong you, of areas we our you employees significant people the diabetes all today, and each to dedication, We and make across of I and insulin these

Operator

Ladies wonderful gentlemen, you for have your and Thank today's a this concludes conference. day. participation, and

all disconnect. may You

Insulet (PODD) 7 Nov 242024 Q3 Earnings call transcript